Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advaxis completes patient enrollment for cancer vaccine
The patient enrollment commenced after dosing 15 patients in an escalating dose clinical trial that was conducted in Mexico, Serbia and Israel. The objective of this trial was
The patient enrollment commenced after dosing 15 patients in an escalating dose clinical trial that was conducted in Mexico, Serbia and Israel. The objective of this trial was
The US regulator approved an additional 0.9mg dose strength tablet, which will be added to the Company’s existing Enjuvia product line that includes the 0.3mg, 0.45mg, 0.625mg, and
Rituximab is currently co-marketed by Biogen Idec and Genentech in the US market as Rituxan, and Roche in the EU as MabThera. Dr Anji Reddy, chairman of Dr
An estimated 80,000 HIV patients in the US have HIV-associated adipose redistribution syndrome (HARS), according to published reports. This disorder is marked by abnormal metabolism, including central fat
Under the terms of the agreement, Sangamo will provide Genentech with access to the company's proprietary zinc finger DNA-binding protein (ZFP) technology. Financial terms of the agreement were
The companies plan to evaluate the ability of Pro-Pharmaceuticals' carbohydrate compounds to improve the delivery of Digna's novel compounds, to enhance activity against chronic hepatitis C infections. Pro-Pharmaceuticals'
Lead clinical investigator in these clinical trials, James Del Rosso, said: “The option of an effective systemic treatment for rosacea that is devoid of antibiotic activity helps dermatologists
By giving ordinary adult mice a drug – a synthetic designed to mimic fat – Salk Institute scientist Ronald Evans is now able to chemically switch on PPAR-d,
Von Willebrand disease (vWD) is the most common inherited bleeding disorder, affecting about 1% of the US population. Humate-P is the first product specifically for patients with severe
The retrospective analysis of a study conducted in the UK showed that after two years of post-surgical therapy, postmenopausal women with hormone-sensitive early breast cancer treated with Femara